---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015838"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:01:50.630762+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO

## Summary
- License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.
- Private placement: 35.6M shares at $2.25 for $80M gross; closed Nov 19; led by Vivo Capital; cash runway into 2028.
- Leadership additions: Hugh Davis as President/COO + Class III director; Steven Knapp EVP Regulatory & Quality.
- Adopted 2024 Inducement Plan reserving 2M shares; Davis granted options for 375K shares, RSU for 107K shares.

## SEC filing metadata
- accession: 0001558370-24-015838
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/acrs-20241116x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015838
- JSON: https://secwatch.observer/filing/0001558370-24-015838.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015838.txt

## Key facts
- Executive change
  Hugh Davis was appointed as Class III Director at Aclaris Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm
- Executive change
  Neal Walker changed role as President at Aclaris Therapeutics, Inc..
  - Action: will no longer serve role
  - Role: President
  source text: In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm
- Executive change
  Hugh Davis was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.